How we know
Medical review
This site's subject is price. Where it touches clinical ground, it stays inside what public labelling and named trials support, and every page shows who researched it, who medically reviewed it and when.
Current status
Pages are researched by Dr. Parmis, medical researcher (Western University of Health Sciences), and medically reviewed by Dr. Jonathan Snipes, MD (NPI 1821250077) and Kim Callender, NP (FNP-BC, NPI 1144661760). They review each site update. Every page carries an author block with the date of its last medical review; a page that has not changed since an earlier update keeps the date of the review it last received.
Medical review covers the clinical statements on a page: what labelling and named trials support, how compounded products are described, and what a reader should take to their own clinician. It is not an endorsement of any provider, and prices are checked by the pricing desk against each provider's own pages, not by the reviewers.
The review process
- Desk drafts against primary sources. Clinical statements are written only from FDA labelling and named trials with verifiable identifiers. Nothing is drawn from secondary summaries.
- Claim-by-claim check. Each clinical claim is checked against the source it cites, and any claim that cannot be traced is cut rather than softened.
- Named clinician review. The reviewers read the page and the date of their review appears in its author block, together with their names and credentials.
What this site does not do
It does not recommend a medication, a dose, or a provider on clinical grounds. It does not tell you whether a GLP-1 is appropriate for you. It does not interpret your labs, your history or your insurance. Those are conversations with a licensed clinician, and no amount of price research substitutes for one.
On compounded products specifically
This site publishes pricing and program research, not medical advice. Compounded tirzepatide and semaglutide are not FDA-approved products, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are dispensed. Since the FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, compounding copies of the approved products is broadly restricted, and remaining 503A dispensing operates under documented patient-specific need in a contested legal environment. Talk to a licensed clinician before starting, changing or stopping any medication. Prices change; verify at the provider's checkout before you pay.